BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 35597253)

  • 1. Ruxolitinib in patients with polycythemia vera with hydroxyurea resistance or intolerance.
    Venugopal S; Mascarenhas J
    Lancet Haematol; 2022 Jul; 9(7):e462-e463. PubMed ID: 35597253
    [No Abstract]   [Full Text] [Related]  

  • 2. Real-World Dosing Patterns of Ruxolitinib in Patients With Polycythemia Vera Who Are Resistant to or Intolerant of Hydroxyurea.
    Altomare I; Parasuraman S; Paranagama D; Kish J; Lord K; Yu J; Colucci P
    Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):e915-e921. PubMed ID: 34353779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea.
    Alvarez-Larrán A; Garrote M; Ferrer-Marín F; Pérez-Encinas M; Mata-Vazquez MI; Bellosillo B; Arellano-Rodrigo E; Gómez M; García R; García-Gutiérrez V; Gasior M; Cuevas B; Angona A; Gómez-Casares MT; Martínez CM; Magro E; Ayala R; Del Orbe-Barreto R; Pérez-López R; Fox ML; Raya JM; Guerrero L; García-Hernández C; Caballero G; Murillo I; Xicoy B; Ramírez MJ; Carreño-Tarragona G; Hernández-Boluda JC; Pereira A;
    Cancer; 2022 Jul; 128(13):2441-2448. PubMed ID: 35417564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cases in the management of polycythemia vera: switching from hydroxyurea to ruxolitinib to resolve symptoms and improve quality of life.
    Verstovsek S
    Clin Adv Hematol Oncol; 2022 Jun; 20 Suppl 11(6):1-12. PubMed ID: 35772008
    [No Abstract]   [Full Text] [Related]  

  • 5. Ruxolitinib is effective and safe in Japanese patients with hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera with splenomegaly.
    Kirito K; Suzuki K; Miyamura K; Takeuchi M; Handa H; Okamoto S; Gadbaw B; Yamauchi K; Amagasaki T; Ito K; Hino M
    Int J Hematol; 2018 Feb; 107(2):173-184. PubMed ID: 28956263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ruxolitinib in patients with polycythemia vera resistant and/or intolerant to hydroxyurea: European observational study.
    Theocharides A; Gisslinger H; De Stefano V; Accurso V; Iurlo A; Devos T; Egyed M; Lippert E; Delgado RG; Cantoni N; Dahm AEA; Sotiropoulos D; Houtsma E; Smyth A; Iqbal A; Di Matteo P; Zuurman M; Te Boekhorst PAW
    Eur J Haematol; 2024 Mar; 112(3):379-391. PubMed ID: 37899734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ruxolitinib discontinuation in polycythemia vera: Patient characteristics, outcomes, and salvage strategies from a large multi-institutional database.
    Tremblay D; Ronner L; Podoltsev N; Gotlib J; Heaney M; Kuykendall A; O'Connell C; Shammo JM; Fleischman A; Mesa R; Yacoub A; Hoffman R; Moshier E; Zubizarreta N; Mascarenhas J
    Leuk Res; 2021 Oct; 109():106629. PubMed ID: 34082375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study.
    Kiladjian JJ; Zachee P; Hino M; Pane F; Masszi T; Harrison CN; Mesa R; Miller CB; Passamonti F; Durrant S; Griesshammer M; Kirito K; Besses C; Moiraghi B; Rumi E; Rosti V; Blau IW; Francillard N; Dong T; Wroclawska M; Vannucchi AM; Verstovsek S
    Lancet Haematol; 2020 Mar; 7(3):e226-e237. PubMed ID: 31982039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polycythaemia vera, ruxolitinib, and hydroxyurea: where do we go now?
    Spivak JL
    Lancet Haematol; 2020 Mar; 7(3):e184-e185. PubMed ID: 31982040
    [No Abstract]   [Full Text] [Related]  

  • 10. The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF).
    Mesa R; Vannucchi AM; Yacoub A; Zachee P; Garg M; Lyons R; Koschmieder S; Rinaldi C; Byrne J; Hasan Y; Passamonti F; Verstovsek S; Hunter D; Jones MM; Zhen H; Habr D; Martino B
    Br J Haematol; 2017 Jan; 176(1):76-85. PubMed ID: 27858987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Outcomes of Ruxolitinib Treatment for Polycythemia Vera.
    Coltoff A; Mesa R; Gotlib J; Shulman J; Rampal RK; Siwoski O; Yacoub A; Moliterno A; Yang A; Braunstein E; Gerds AT; Hobbs GS; Winton EF; Goel S; Wadleigh M; Tremblay D; Moshier E; Mascarenhas J
    Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):697-703.e1. PubMed ID: 32624445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of hydroxyurea-resistant/intolerant polycythemia vera: a discussion of best practices.
    Kuykendall AT
    Ann Hematol; 2023 May; 102(5):985-993. PubMed ID: 36944847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy and Safety of Ruxolitinib in Polycythemia Vera].
    Chang L; Duan MH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1515-1518. PubMed ID: 36208258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ruxolitinib versus standard therapy for the treatment of polycythemia vera.
    Vannucchi AM; Kiladjian JJ; Griesshammer M; Masszi T; Durrant S; Passamonti F; Harrison CN; Pane F; Zachee P; Mesa R; He S; Jones MM; Garrett W; Li J; Pirron U; Habr D; Verstovsek S
    N Engl J Med; 2015 Jan; 372(5):426-35. PubMed ID: 25629741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies.
    Sekhri R; Sadjadian P; Becker T; Kolatzki V; Huenerbein K; Meixner R; Marchi H; Wallmann R; Fuchs C; Griesshammer M; Wille K
    Ann Hematol; 2021 Nov; 100(11):2707-2716. PubMed ID: 34462786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera?
    Nazha A; Gerds AT
    Oncologist; 2016 Apr; 21(4):475-80. PubMed ID: 26975864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy findings from the open-label, multicenter, phase 3b, expanded treatment protocol study of ruxolitinib for treatment of patients with polycythemia vera who are resistant/intolerant to hydroxyurea and for whom no alternative treatments are available.
    Foltz L; Pica GM; Zerazhi H; Van Droogenbroeck J; Visanica S; Báez de la Fuente E; Leber B; de Almeida AM; Ranta D; Kiladjian JJ; Chrit L; Kandra A; Morando J; Devos T
    Leuk Lymphoma; 2019 Dec; 60(14):3493-3502. PubMed ID: 31359808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide.
    Harrison CN; Griesshammer M; Miller C; Masszi T; Passamonti F; Zachee P; Durrant S; Pane F; Guglielmelli P; Verstovsek S; Jones MM; Hunter DS; Sun W; Li J; Khan M; Habr D; Kiladjian JJ
    Br J Haematol; 2018 Jul; 182(2):279-284. PubMed ID: 29984424
    [No Abstract]   [Full Text] [Related]  

  • 19. Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study.
    Passamonti F; Griesshammer M; Palandri F; Egyed M; Benevolo G; Devos T; Callum J; Vannucchi AM; Sivgin S; Bensasson C; Khan M; Mounedji N; Saydam G
    Lancet Oncol; 2017 Jan; 18(1):88-99. PubMed ID: 27916398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study.
    Passamonti F; Palandri F; Saydam G; Callum J; Devos T; Guglielmelli P; Vannucchi AM; Zor E; Zuurman M; Gilotti G; Zhang Y; Griesshammer M
    Lancet Haematol; 2022 Jul; 9(7):e480-e492. PubMed ID: 35597252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.